# A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

Source: https://onco.cc/trials/dllevate/  
OnCo record `dllevate` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing ZL-1310 in non-small-cell lung cancer, now recruiting.

## Summary

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) is a phase 3 interventional study registered as NCT07218146, led by Zai Lab (Shanghai) with Zai Lab (US), and recruiting on the registry. Official title: A Randomised, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer. Planned enrolment is 480 participants (estimated). The study started in 2025-11-30 and primary completion is expected in 2028-06-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: DLLEVATE
- Tags: ctgov-ingest
- Registry id: NCT07218146
- Phase: 3
- Setting: A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer
- Sponsor: Zai Lab (Shanghai)
- Enrolled: 480

## Sources

- ClinicalTrials.gov NCT07218146: https://clinicaltrials.gov/study/NCT07218146

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [ZL-1310](https://onco.cc/drugs/zl-1310/)
- companies: [Zai Lab](https://onco.cc/companies/zai-lab/)

---
JSON: https://onco.cc/api/v1/entities/dllevate.json